Simple Summary Growth factors are hormone-like molecules able to promote division and
migration of normal cells, but cancer captured the underlying mechanisms to unleash tumor …

Over the past decade, remarkable advances have been witnessed in the development of
small-molecule probes. These molecular tools have been widely applied for interrogating …

Background Osimertinib is an oral, third-generation, irreversible epidermal growth factor
receptor tyrosine kinase inhibitor (EGFR-TKI) that selectively inhibits both EGFR-TKI …

Here, we show that microfluidic organ-on-a-chip (organ chip) cell culture technology can be
used to create in vitro human orthotopic models of non-small-cell lung cancer (NSCLC) that …

In the past two decades, several molecular targeted inhibitors have been developed and
evaluated clinically to improve the survival of patients with cancer. Molecular targeted …

Significant progress has been made in the understanding of lung cancer biology, due in
large part to advancement in the understanding of tumor biology and pathogenesis …

Non-small cell lung cancer (NSCLC) is the most common type of lung cancer, accounting for
80–85% of cases. Epidermal growth factor receptor (EGFR) mutations are observed in …

Purpose: The expanding number of targeted therapeutics for non–small cell lung cancer
(NSCLC) necessitates real-time tumor genotyping, yet tissue biopsies are difficult to perform …

Our increasing understanding of cancer biology has led to the development of molecularly
targeted anticancer drugs. The full potential of these agents has not, however, been …

Acquired T790 M mutation is the commonest cause of resistance for advanced non-small
cell lung cancer (NSCLC) epidermal growth factor receptor (EGFR) mutant patients who had …